Digital Therapeutics Market Report 2026

Digital Therapeutics Market Overview

• Digital Therapeutics market size has reached to $10.93 billion in 2025 • Expected to grow to $37.82 billion in 2030 at a compound annual growth rate (CAGR) of 28.1% • Growth Driver: Rising Tide Of Chronic Diseases Fueling The Growth Of Digital Therapeutics • Market Trend: Prescription Digital Therapeutics Adoption To Improve Chronic Disease Management • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

The key promising market opportunities in the digital therapeutics market include: • Software (Segmentation By Product) → Expected gain of $16.87 Billion • Devices (Segmentation By Product) → Expected gain of $9.81 Billion

What Is Covered Under Digital Therapeutics Market?

Digital therapeutics (DTx) are the products that give evidence-based therapeutic treatments to patients through high-quality software applications in order to prevent, manage, or treat a medical ailment or disease. The main product types of digital therapeutics are devices and software. Digital therapeutics devices provide intervention to prevent, manage or treat a disease or medical disorder. This includes devices such as sensors used to track medication usage and location data. The different sales channels include business-to-business (B2B), business-to-consumer (B2C). Digital therapeutics are used in preventive applications and treatment or care-related applications.

What Is The Digital Therapeutics Market Growth Forecast?

The digital therapeutics market size is expected to see exponential growth in the next few years. It will grow to $37.82 billion in 2030 at a compound annual growth rate (CAGR) of 28.1%. The growth in the forecast period can be attributed to increasing reimbursement support for digital therapeutics, rising demand for personalized digital care, expansion of ai-driven treatment platforms, growing partnerships between healthcare providers and tech firms, increasing focus on preventive digital health. Major trends in the forecast period include increasing adoption of software-based therapeutic solutions, rising integration of wearable health devices, growing use of remote patient monitoring platforms, expansion of evidence-based digital care programs, enhanced focus on personalized treatment pathways.

What Is The Driver Of The Digital Therapeutics Market?

The growing prevalence of chronic diseases is expected to propel the growth of the digital therapeutics market going forward. Chronic diseases are long-lasting conditions that usually last for one year or more and require ongoing medical attention or limit activities of daily living, or both. Digital therapeutics are software-based interventions that deliver evidence-based therapeutic interventions to patients to enhance chronic disease management and offer more treatment options. For instance, in March 2025, according to the Office for Health Improvement & Disparities (OHID), a UK-based unit of the Department of Health and Social Care, the GP recorded type 2 diabetes prevalence in adults as 7.0% for those aged 17 and over in England in March 2024, which was an increase from 6.8% in March 2023. Therefore, the growing prevalence of chronic diseases drives the growth of the digital therapeutics industry.

How Will The Drivers Impact Growth In The Global Digital Therapeutics Market?

• Rising Prevalence Of Chronic Diseases (High) – During the forecast period, the rising prevalence of chronic diseases is expected to become a key growth driver for the digital therapeutics market by 2030. The growing burden of diabetes, cardiovascular diseases, respiratory disorders, and mental health conditions is increasing the need for continuous, personalized, and evidence-based treatment solutions beyond traditional clinical settings. Digital therapeutics enable long-term disease management through real-time monitoring, behavioural interventions, and clinically validated treatment programs that improve patient outcomes while reducing healthcare costs. Healthcare providers are therefore expanding the use of digital interventions to support chronic disease care at scale. • Growing Adoption Of Remote Healthcare (High) – During the forecast period, the growing adoption of remote healthcare is expected to emerge as a major factor driving the expansion of the digital therapeutics market by 2030. The widespread use of telehealth services is encouraging healthcare providers to incorporate digital therapeutics into virtual care pathways, enabling continuous patient engagement outside hospitals and clinics. These solutions facilitate remote monitoring, personalized therapy delivery, and timely clinical interventions while improving treatment adherence and accessibility. The ongoing shift toward home-based healthcare models is further strengthening demand for digital therapeutic platforms. • Increasing Smartphone And Internet Penetration (High) – During the forecast period, the increasing smartphone and internet penetration is expected to act as a key growth catalyst for the digital therapeutics market by 2030. Greater access to smartphones, high-speed internet, and connected digital ecosystems is expanding the reach of therapeutic applications across both developed and emerging markets. Improved digital connectivity enables patients to conveniently access prescribed therapeutic programs, receive personalized health guidance, and maintain continuous interaction with healthcare professionals through mobile platforms. As digital infrastructure continues to improve globally, adoption of digital therapeutics is expected to accelerate across a broader patient population.

How Will The Restraints Impact Growth In The Global Digital Therapeutics Market?

• Limited Reimbursement Policies (High) – During the forecast period, the limited Reimbursement Policies are restricting large-scale adoption of digital therapeutics because many healthcare systems lack clear payer coverage and reimbursement frameworks. StrategyMRC Restraint Data Privacy And Cybersecurity Concerns Data Privacy And Cybersecurity Concerns are reducing patient and provider trust due to risks of healthcare data breaches and unauthorized access to sensitive medical information. 360 Research Reports Restraint Lack Of Standardized Clinical Evidence Lack Of Standardized Clinical Evidence is slowing regulatory approvals and physician adoption because healthcare providers require validated proof of therapeutic effectiveness. Transcript IQ • Data Privacy And Cybersecurity Concerns (High) – During the forecast period, the data Privacy And Cybersecurity Concerns are reducing patient and provider trust due to risks of healthcare data breaches and unauthorized access to sensitive medical information • Lack Of Standardized Clinical Evidence (High) – During the forecast period, the lack Of Standardized Clinical Evidence is slowing regulatory approvals and physician adoption because healthcare providers require validated proof of therapeutic effectiveness.

Key Players In The Global Digital Therapeutics Market

Major companies operating in the digital therapeutics market are Omada Health Inc., WellDoc Inc., 2Morrow Inc., Propeller Health, Pear Therapeutics, Canary Health Inc., Noom Health Inc., Akili Interactive Labs, Better Therapeutics, Happify Health, Kaia Health, Medtronic plc, Teladoc Health Inc., Fitbit Health Solutions, EMulate Therapeutics, BigHealth, DarioHealth, IQVIA, JOGO Health, SilverCloud Health, Biofourmis Inc., Prosoma, Virta Health Corp., One Drop Inc., Lark Health, Xealth, CogniFit Ltd.

Global Digital Therapeutics Market Trends and Insights

Major companies are operating in the digital therapeutics market, focusing on developing technological advancements such as prescription-only digital behavioral therapy platforms to enhance treatment accessibility, improve patient engagement, and provide clinically validated outcomes. A prescription-only digital behavioral therapy platform uses software-based interventions delivered via smartphone or tablet with evidence-based modules such as cognitive behavioral therapy (CBT), remote monitoring, and interactive goal tracking, allowing scalable, drug-free disease management and personalized patient support. For instance, in July 2023, Better Therapeutics, a US-based prescription digital therapeutics company, launched AspyreRx (formerly BT‑001), a digital therapeutic for type 2 diabetes. The product delivers a 90-day self-paced program through a smartphone app, featuring weekly CBT lessons, personalized goal-setting, and tracking of blood glucose and lifestyle data; clinical trials demonstrated sustained reductions in HbA1c, weight improvement, and better quality-of-life outcomes.

What Are Latest Mergers And Acquisitions In The Digital Therapeutics Market?

In July 2023, Big Health, a US-based provider of digital therapeutics, acquired Limbix for an undisclosed amount. The acquisition would broaden Big Health's existing product portfolio, which includes Sleepio for insomnia and Daylight for anxiety, as well as Limbix's SparkRx and another teenage medication in development for anxiety. Limbix is a US-based provider of digital therapeutics.

What Defines the Digital Therapeutics Market?

The digital therapeutics market consists of sales of products to treat a disease, manage a condition, and improve a health function. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Digital Therapeutics Market Report 2026?

The digital therapeutics market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the digital therapeutics industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.